Check Before You Invest : Panacea Biotec Ltd

Q: Which industry/sub-sector does Panacea Biotec Ltd belong to?

Panacea Biotec Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q: Is Panacea Biotec Ltd a good quality company?

Panacea Biotec Ltd is a weak quality company, based on a inconsistent multi-year financial track record. This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q: Is Panacea Biotec Ltd undervalued or overvalued?

Panacea Biotec Ltd appears Overvalued, as its key valuation ratios are higher than their past averages. Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more. Valuation Ratios. Price to Earnings, Current: -, Historic Median: -. Price to Book, Current: 9.14, Historic Median: 2.95. Price to Sales, Current: 7.02, Historic Median: 4.20. EV to EBITDA, Current: -156.72, Historic Median: 18.27

Q: Is Panacea Biotec Ltd a good buy now?

Panacea Biotec Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Q: Revenue growth of Panacea Biotec Ltd?

Panacea Biotec Ltd revenue growth is -13.8% for FY-2025, which is below its 5-year CAGR of -8.75%, indicating slower growth.

Q: Gross Profit margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Gross profit margin which is the profit after deduction of direct costs, is -1.9% for FY-2025, which is in line with its 5-year median of -1.9%, indicating stable margins.

Q: Operating Profit Margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -2.24% for FY-2025, which is in line with its 5-year median of -2.24% indicating stable margins.

Q: Net Profit Margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Net Profit Margin is -4.91% for FY-2025, is in line with its 5-year median of -4.91%, indicating stable margins. Profitability Metrics. Gross Profit Margin (%), Current: -1.9, Historic Median: -1.9. Operating Profit Margin (%), Current: -2.24, Historic Median: -2.24. Net Profit Margin (%), Current: -4.91, Historic Median: -4.91

Q: Return on Asset of Panacea Biotec Ltd?

Panacea Biotec Ltd Return on Asset is -1.69%, which is in line with its 5-year historical median of -1.69%, indicating stable asset utilization efficiency.

Q: Return on capital employed (ROCE) of Panacea Biotec Ltd?

Panacea Biotec Ltd Return on capital employed is -2.13% for FY-2025, which is in line with its 5-year historical median of -2.13%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Check Before You Invest : Panacea Biotec Ltd

Snapshot

Q.1 Which industry/sub-sector does Panacea Biotec Ltd belong to?

Panacea Biotec Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.

Q.2 Is Panacea Biotec Ltd a good quality company?

Panacea Biotec Ltd is a weak quality company, based on a inconsistent multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

Q.3 Is Panacea Biotec Ltd undervalued or overvalued?

Panacea Biotec Ltd appears Overvalued, as its key valuation ratios are higher than their past averages.

Based on the industry it operates in, the relevant valuation ratios include one of the following, P/E, P/BV, P/Sales, EV/EBITDA or a combination of two or more.

Valuation Ratios	Current	5-year Historic Median
Price to Earnings	-	-
Price to Book	9.14	2.95
Price to Sales	7.02	4.20
EV to EBITDA	-156.72	18.27

Q.4 Is Panacea Biotec Ltd a good buy now?

Panacea Biotec Ltd is a good buy now, based on strong price trend analysis suggesting prices may rise. However, you need to check its quality and valuation before making a decision

Performance Analysis

We have analysed the performance of the company on the following:

How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.

A: What are the trends in revenue and profit margins?

Q.1 Revenue growth of Panacea Biotec Ltd?

Panacea Biotec Ltd revenue growth is -13.8% for FY-2025, which is below its 5-year CAGR of -8.75%, indicating slower growth.

Q.2 Gross Profit margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Gross profit margin which is the profit after deduction of direct costs, is -1.9% for FY-2025, which is in line with its 5-year median of -1.9%, indicating stable margins.

Q.3 Operating Profit Margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -2.24% for FY-2025, which is in line with its 5-year median of -2.24% indicating stable margins.

Q.4 Net Profit Margin of Panacea Biotec Ltd?

Panacea Biotec Ltd Net Profit Margin is -4.91% for FY-2025, is in line with its 5-year median of -4.91%, indicating stable margins.

	Current Level	5-year Historic Median
Gross Profit Margin (%)	-1.9	-1.9
Operating Profit Margin (%)	-2.24	-2.24
Net Profit Margin (%)	-4.91	-4.91

B: Does the business utilize capital efficiently?

Q.5 Return on Asset of Panacea Biotec Ltd?

Panacea Biotec Ltd Return on Asset is -1.69%, which is in line with its 5-year historical median of -1.69%, indicating stable asset utilization efficiency.

Q.6 Return on capital employed (ROCE) of Panacea Biotec Ltd?

Panacea Biotec Ltd Return on capital employed is -2.13% for FY-2025, which is in line with its 5-year historical median of -2.13%. The current ROCE is below its estimated weighted average cost of capital (WACC) of 14%, indicating value preservation.

Q.7 Return on Equity (ROE) of Panacea Biotec Ltd?

Panacea Biotec Ltd Return on equity is -4.74% for FY-2025, which is in line with its 5-year historical median of -4.74%, indicating the business is making similar use of its shareholders capital.

Q.8 Cash conversion cycle of Panacea Biotec Ltd?

Panacea Biotec Ltd Cash conversion cycle is 14 days, in line with its 5-year historical median of 14 days, indicating stable working capital management. However, you need to compare this with its peers in the industry.

	Current Level	5-year Historic Median
Asset Turnover (x)	0.34	0.31
ROE (%)	-4.74	-4.74
ROCE (%)	-2.13	-2.13
Cash Conversion Cycle	14 days	14 days

C: How much debt does the business have and is it at a sustainable level?

Q.9 Debt to Equity ratio of Panacea Biotec Ltd?

Panacea Biotec Ltd Debt-to-Equity ratio is 0.73, which is above the industry average of 0.14, indicating higher debt levels in the industry.

Q.10 Debt to cash flow from operations of Panacea Biotec Ltd?

Panacea Biotec Ltd Debt to cash flow from operations is 57.97, which is at a unhealthy level.

Ownership & governance

D: Promoter shareholding and pledge status of Panacea Biotec Ltd?

Q.1 Promoter shareholding and pledge status of Panacea Biotec Ltd?

Promoters hold 72.48% of the Panacea Biotec Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

E: How does Panacea Biotec Ltd performance compare with that of its Peers?

Q.1 Revenue growth of Panacea Biotec Ltd vs industry peers?

Panacea Biotec Ltd revenue CAGR is -8.75%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.

Profit Metrics

	Current Level	5-year Industry Median
Revenue Growth (%)	-13.8	5.4
Gross Profit Growth (%)	-124	14
Operating Profit Growth (%)	-150	11.5
Net Profit Growth (%)	-475	12

Operating Efficiency

	Current Level	5-year Industry Median
Asset Turnover (x)	0.34	0.79
ROE (%)	-4.74	9.17
ROCE (%)	-2.13	11.52
Cash Conversion Cycle (days)	14.25	76

Valuation & price assessment

Q.1 Stock return of Panacea Biotec Ltd over the last decade?

Over the last 9 year(s), the stock has delivered a CAGR of 16.9% based on the current price.

	9Y	5Y	3Y	1Y
Share Price CAGR	16.9%	2.5%	53.3%	-16.5%

Q.2 Valuation ratios of Panacea Biotec Ltd vs historical?

The current P/E ratio of 0 is in line with than its historical median of , indicating that the stock is trading near its historical average valuation.

Q.3 How do the current valuation ratios compare with 5-year historical median and industry numbers?

Valuation Ratios	Current	5-year Historic Median	5-year Industry Median
Price to Earnings	-	-	31.09
Price to Book	9.14	2.95	2.85
Price to Sales	7.02	4.20	2.82
EV to EBITDA	-156.72	18.27	15.99

Check more companies

3. Wockhardt

8. Neuland Laboratories

9. Astrazeneca Pharma I

10. Onesource Specialty

Check trending companies

1. Carborundum Universal Ltd.

2. Praj Industries Ltd.

3. MRF Ltd.

4. Reliance Power Ltd.

5. Bharat Heavy Electricals Ltd.

Check Before You Invest : Panacea Biotec Ltd

Snapshot

Performance Analysis

Ownership & governance

Peer comparison (industry-wise, mcap)

Profit Metrics

Operating Efficiency

Valuation & price assessment

Check more companies

Check trending companies

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.